SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) in an aggressive malignancy with suboptimal response to frontline chemotherapy and without established second line treatment. cMET activation is associated with ACC resistance to chemotherapy. Cabozantinib is a multi-kinase inhibitor that targets the VEGFR,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Adrenal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209711/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.508
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars